ANNX - Annexon Inc logo

ANNX

Annexon Inc

Rev —top 1%5Y
Hold

Annexon Inc is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for inflammatory diseases. Its key products include monoclonal antibodies and small molecules in various clinical trial phases for conditions like Guillain-Barré syndrome and Huntington's disease.

⚕️ Healthcare NASDAQ Listed 2020 $ USD
$1,000 invested 5 years ago $270today

Score Overview

1 Year
Score
Net Growth4.94%
Net TrendGrew
Net Income Consistency
Rev Growth
Rev TrendShrank
Revenue Consistency
5 Years
Score
Net Growth-53.75%
Net Trend40%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency
All Time
Score
Net Growth-213.13%
Net Trend33%
Net Income Consistency
Rev Growth
Rev TrendNever
Revenue Consistency

See the full market ranking →

Annexon Inc fundamental performance

Across Annexon Inc's full reported history, from 2020 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 62M to -$ 206M. Revenue increased in 0% of the years measured; net income in 33%.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 5.33
1 Year2025-08-12
$ 2.44118.44%
5 Years2021-08-12
$ 19.73-72.99%
All Time2020-07-24
$ 17.76-69.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 196M$ 225M
2025$ 0.00-$ 206M$ 238M
2024$ 0.00-$ 138M$ 312M
2023$ 0.00-$ 134M$ 259M
2022$ 0.00-$ 138M$ 242M
2021$ 0.00-$ 127M$ 242M
IPO2020$ 0.00-$ 62M$ 351M

Explore beyond ANNX

You're looking at Annexon Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies